A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
A phase 1/2 trial of ETX-19477 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by 858 Therapeutics, Inc., now recruiting.
Overview
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06395519 by 858 Therapeutics, Inc., with 120 participants planned, started 2024-05-13 and due to reach its primary completion in 2026-12. Interventions recorded: ETX-19477.
Similar pages
not linked directly; found by shared links- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Prostate cancer and the tag pipeline.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialA Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.